US FDA OK's subcu Orencia for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb won US approval of its subcutaneous formulation of its rheumatoid arthritis drug Orencia (abatacept) as a therapy to reduce the signs and symptoms, induce major clinical response, inhibit the progression of structural damage and improve physical function in adults with moderate to severe active disease.